Sector News

Alexion Names David Hallal COO

September 18, 2014
Life sciences
(RTTNews) – Alexion Pharmaceuticals, Inc., whose durg Soliris treats two rare diseases, Wednesday said it is promoting David Hallal to the newly created position of chief operating officer.
 
Hallal, who joined the company in 2006, was previously its executive vice president and chief commercial officer. He led the launch of Soliris. Before Alexion, he was worked at Biogen Idec and Amgen.
 
The company also promoted two members of the management to executive vice president from vice president: Chief Human Resources Officer Clair Carmichael ; and General Counsel John Moriarty.
 
The company further said it appointed Edward Miller to the nearly created position of Senior Vice President and Chief Compliance Officer.
 

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend